CCR2 and breast cancer: In mouse models of breast cancer, it was demonstrated that depleting C-C chemokine receptor type 2+ (CCR2) inflammatory monocytes resulted in the loss of 96% of tumour-associated monocytes together with ~93% of TAMs [43].